Sun Pharmaceutical Industries share news, announcements and annual reports
NSE: SUNPHARMABSE: 524715Pharmaceuticals & BiotechnologyLarge Cap
Sun Pharmaceutical Industries Limited · Formerly Sun Pharmaceuticals Industries · Face value ₹1 Face value. The nominal value of one share as the company issued it, the unit its share capital is counted in and a dividend can be stated as a percentage of; it has no link to the share price. Face value in the glossary · Listed Dec 1994 on BSE, Feb 1995 on NSE
Last close ₹1,761.00up ₹3.50 (0.20%)BSE ₹1,762.95
Share price at the NSE close on 29 Oct 2026. Previous close ₹1,757.50.
29 Oct: open ₹1,757.50, high ₹1,771.50, low ₹1,752.70
52-week range of traded prices to 29 Oct 2026
₹1,583.70Low, 29 Jan 2026₹2,046.90High, 31 Jul 2026
- Next results date: the board meets on 30 Oct 2026 to consider: financial results. The notice · Results calendar
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies. Market capitalisation: how it is worked out
- ₹4,22,523 Cr13th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- 34.93
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Price to book: how it is worked out
- 5.06
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- 0.91%
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it.
- 15.5%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet.
- 16.9%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026.
- 0.05
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day. Volume in the glossary
- 11,07,85459.5% delivered
Sun Pharmaceutical Industries disputes and clarifications
39 filed, newest first.
Feb 2025
4 Feb · Legal
Nov 2024
28 Nov · Legal
26 Nov · Legal
6 Nov · Legal
5 Nov · Legal
Oct 2024
11 Oct · Legal
7 Oct · Legal
Mar 2022
May 2019
13 May · Legal
Exchange has sought clarification from the Company with respect to news item captioned- titled "Pharma stocks bleed as US states file lawsuit against generic drug firms". In this regard, you are advised to provide clarification/confirmation on the news item in detail including the following: a) Whether such event stated in published news were taking place? If so, you are advised to provide the said information along with the sequence of events in chronological order. b) The material impact of this article on the Company. c) Whether company was aware of any information that has not been announced to the Exchanges under Regulation 30 of Listing Regulations. If so, you are advised to provide the said information and the reasons for not disclosing the same to the Exchange earlier as required under Regulation 30 of the Listing Regulations. The response from the Company is awaited.
Apr 2019
25 Apr · Legal
Exchange has sought clarification from the Company with respect to news item captioned- " US FDA Finds quality, data issues at Dadra plant of Sun Pharma ". In this regard, you are advised to provide clarification/confirmation on the news item in detail including the following: a) Whether such event stated in published news were taking place? If so, you are advised to provide the said information along with the sequence of events in chronological order. b) The material impact of this article on the Company. c) Whether company are aware of any information that has not been announced to the Exchanges under Regulation 30 of Listing Regulations. If so, you are advised to provide the said information and the reasons for not disclosing the same to the Exchange earlier as required under Regulation 30 of the Listing Regulations. The response from the Company is awaited.
Mar 2019
22 Mar · Legal
Exchange has sought clarification from the Company with respect to news item captioned- " Sun Pharma falls 1% on USFDA observation for Baska facility ". In this regard, you are advised to provide clarification/confirmation on the news item in detail including the following: a) Whether such event stated in published news were taking place? If so, you are advised to provide the said information along with the sequence of events in chronological order. b) The material impact of this article on the Company. c) Whether company are aware of any information that has not been announced to the Exchanges under Regulation 30 of Listing Regulations. If so, you are advised to provide the said information and the reasons for not disclosing the same to the Exchange earlier as required under Regulation 30 of the Listing Regulations. The response from the Company is awaited.
Dec 2018
Sep 2018
11 Sep · Legal
Exchange has sought clarification from the Company with respect to news item captioned-Sun Pharma Mohali plant on FDA radar In this regard, Exchange has advised the Company to provide clarification/confirmation on the news item in detail including the following: a) Whether such event/negotiations/article stated in published news were taking place? If so, you are advised to provide the said information along with the sequence of events in chronological order and the material impact of this article on the Company. b) Whether company is aware of any information that has not been announced to the Exchanges under regulation 30 of Listing Regulations. The response from the Company is awaited.
Jul 2018
12 Jul · Legal
Exchange has sought clarification from Sun Pharmaceutical Industries Limited with respect to announcement dated 11-Jul-2018, regarding " Sun Pharmaceutical Industries Limited has informed the Exchange regarding a press release dated July 11, 2018, titled "DUSA Pharmaceuticals, Inc. files lawsuit against Biofrontera Inc. for patent infringement, trade secret misappropriation, and tortious interference".". On basis of above the Company is required to clarify following: 1. Quantum of claims, if any 2. Expected financial implications, if any, due to compensation, penalty etc; 3. Brief details of litigation viz. name(s) of the opposing party, court/ tribunal/agency where litigation is filed, brief details of dispute/litigation; The response of the Company is awaited.
Feb 2018
5 Feb · Legal
Exchange has sought clarification from the Company with respect to news item captioned "Fire at Sun Pharma's Ankleshwar plant, company says no casualties. In this regard, Exchange has advised the Company to provide clarification/confirmation on the news item in detail including the following: a) Whether such event/negotiations/article stated in published news were taking place? If so, you are advised to provide the said information along with the sequence of events in chronological order and the material impact of this article on the Company. b) Whether company is aware of any information that has not been announced to the Exchanges under regulation 30 of Listing Regulations. The response from the Company is awaited.
Apr 2017
21 Apr · Legal
Exchange has sought clarification from the Company with respect to news item captioned "FDA issues 11 observations for Dadra unit". In this regard, Exchange has advised the Company to provide clarification/confirmation on the news item in detail including the following: a) Whether such event/negotiations/article stated in published news were taking place? If so, you are advised to provide the said information along with the sequence of events in chronological order and the material impact of this article on the Company. b) Whether company is aware of any information that has not been announced to the Exchanges under regulation 30 of Listing Regulations. The response from the Company is awaited.
Jan 2017
23 Jan · Legal
Exchange has sought clarification from the Company with respect to recent news item captioned Sun Pharma to Sell Ohm Labs Site At New Jersey In The US; Ohm Labs Site Could Fetch Co Up To $100 m .In this regard, Exchange has advised the Company to provide clarification/confirmation on the news item in detail including the following: a) Whether such event/negotiations/article stated in published news were taking place? If so, you are advised to provide the said information along with the sequence of events in chronological order and the material impact of this article on the Company. b) Whether company is aware of any information that has not been announced to the Exchanges under regulation 30 of Listing Regulations. The response from the Company is awaited.
Dec 2016
29 Dec · Legal
Exchange has sought clarification from Sun Pharmaceuticals Industries Limited with respect to recent news item captioned "Blast at Sun Pharma unit'.In this regard, Exchange has advised the Company to provide clarification/confirmation on the news item in detail including the following: a) Whether such event/negotiations/article stated in published news were taking place? If so, you are advised to provide the said information along with the sequence of events in chronological order and the material impact of this article on the Company. b) Whether company is aware of any information that has not been announced to the Exchanges under regulation 30 of Listing Regulations. The response from the Company is awaited.
Sep 2015
11 Sep · Legal
Exchange had sought clarification from Sun Pharmaceuticals Industries Limited with respect to a news item captioned "Sun Pharma looking to divest Ireland plant". The Company has clarified as follows:a. We hereby confirm that following Sun Pharma's successful completion of Ranbaxy merger, there is an opportunity to optimize overall manufacturing network. As a result, decisions are being made by the Company / the Company' subsidiary companies to either close or divest some of the Company's/subsidiaries' manufacturing facilities respectively. Currently, the Ireland facility has been identified for divestment. Whenever the divestment process for this facility is complete, statutory disclosures, as may be required, will be made. We further state that such proposed divestment has no/would have no material impact on Company's performance, operations or revenues. b. No. The Company is not aware of any information that has not been announced to the Exchanges under clause 36 of the Listing Agreement.11 Sep · Legal
Exchange has sought clarification from Sun Pharmaceuticals Industries Limited with respect to recent news item captioned "Sun Pharma looks to divest Irish unit". In this regard, Exchange have advised the Company to provide clarification/confirmation on the news item in detail including the following: a) Whether such event/negotiations/article stated in published news were taking place? If so, you are advised to provide the said information along with the sequence of events in chronological order and the material impact of this article on the Company. b) Whether company are aware of any information that has not been announced to the Exchanges under clause 36 of the Listing Agreement. The response from the Company is awaited.
Nov 2014
17 Nov · Legal
Exchange had sought clarification from Sun Pharmaceuticals Industries Limited with respect to a news item captioned "Sun Pharma Merck Call Off 3-year-old JV". The Company has clarified as follows: a) Whether such event/negotiations/article stated in published news were taking place? If so, you are advised to provide the said information along with the sequence of events in chronological order and the material impact of this article on the Company. Company's Response : "There is no termination of JV of Sun Pharma with Merck (MSD)". b) Whether company are aware of any information that has not been announced to the Exchanges under clause 36 of the Listing Agreement. If so, you are advised to provide the said information and the reasons for not disclosing the same to the Exchange earlier as required under clause 36 of the Listing Agreement. Company's Response : "No".17 Nov · Legal
Exchange has sought clarification from Sun Pharmaceuticals Industries Limited with respect to recent news item captioned "Sun Pharma Merck Call Off 3-year-old JV". In this regard, Exchange have advised the Company to provide clarification/confirmation on the news item in detail including the following: a) Whether such event/negotiations/article stated in published news were taking place? If so, you are advised to provide the said information along with the sequence of events in chronological order and the material impact of this article on the Company. b) Whether company are aware of any information that has not been announced to the Exchanges under clause 36 of the Listing Agreement. The response from the Company is awaited.
Oct 2014
17 Oct · Legal
Exchange had sought clarification from Sun Pharmaceuticals Industries Limited with respect to news item captioned "Sun, Ranbaxy may be asked to sell some business for CCI approval to merger". The Company has clarified that "(a) We have not received any direction from the Competition Commission of India (CCI) for divesting any business as indicated in the said news article. (b) Further, the Company is not aware of any information that has not been announced to the Exchanges under clause 36 of the Listing Agreement".9 Oct · Legal
Exchange had sought clarification from Sun Pharmaceuticals Industries Limited with respect to a news item captioned "Sun, Dr Reddy's, cadila named in US Congress price probe". The Company has clarified that "We confirm that our subsidiary company has received recently a data request from Representative Cummins and Senator Sanders relating to the price increase of 3 products being distributed by Sun Pharma subsidiary in the US market. The article has no material impact on the Company".
Sep 2014
15 Sep · Legal
Exchange had sought clarification from Sun Pharmaceuticals Industries Limited with respect to news item captioned "Sun Pharma to raise Rs. 12K cr via QIP". The Company has clarified that "Resolutions proposed for approval of the shareholders of the Company at the ensuing 22nd Annual General Meeting to be held on September 27, 2014 regarding issue of securities upto Rs.120 Billions and for borrowings upto Rs.500 bn. are only enabling resolutions. Last year also resolution was proposed for approval of and was approved by the shareholders of the Company at the 21st Annual General Meeting held last year regarding issue of securities almost in the same manner upto the same amount upto Rs.120 Billions as an enabling resolution. Even the resolution seeking shareholder approval, under the new Companies Act 2013, for upper limit of borrowings up to Rs.500 bn was also earlier proposed for approval to and was approved by the shareholders of the Company at the 21st Annual General Meeting held last year with the same upper cap of Rs. 500 billions. There is no material impact of the matter referred to in the article on the performance / operations of the Company."12 Sep · Legal
Exchange had sought clarification from Sun Pharmaceuticals Industries Limited with respect to a news item captioned "US FDA descends on Sun Pharma's Halol unit". The Company had clarified that "Sun Pharma and its subsidiary have more than 15 manufacturing facilities spread across India. It markets products in more than 50 countries; each country has its own pharma regulatory requirements. These manufacturing facilities undergo many routine regulatory inspections from several of these countries as part of normal course of business, from time to time. Conduct of each of these inspections per se has no material impact. Also, informing the stock exchange for every such inspection, which in itself is not material, may be construed inappropriately. If there are any material developments, related to or coming out of such inspections, we will keep the stock exchanges and investors informed of such material developments. Please note there is no material impact of the matter referred to in the article on the performance / operations of the Company".
May 2014
16 May · Legal
Exchange had sought clarification from Sun Pharmaceuticals Industries Limited with respect to a news item captioned "Sun Pharma moves SC against stay on Ranbaxy merger". The Company has clarified that "The facts mentioned under the referred news article are largely true. We further state that there is no material impact of the matter on the process of completion of merger of Ranbaxy Laboratories Ltd with our Company".13 May · Legal
Exchange had sought clarification from Sun Pharmaceuticals Industries Limited with respect to a news item captioned "Sun Pharma recalls over 4 lakh bottles of two drugs in US". The Company has clarified that "The details mentioned in the said article are correct. However, since the recall entails only a few batches of the said drugs from the US market, the overall impact on our sales is negligible. Hence in our view the above information did not/ does not constitute price sensitive information".5 May · Legal
Exchange had sought clarification from Sun Pharmaceuticals Industries Limited with respect to a news item captioned "Sun-Ranbaxy deal hits hurdle". The Company has clarified that "We were not served the notice of the hearing for the AP High Court case referred to and the matter was decided ex parte. Please further note that our subsidiary llp, Silver Street Developers LLP had bought the Ranbaxy shares when we had no access to non-public information of Ranbaxy. We hereby confirm that we had not bought any shares in the period from 1st April to 7th April. Specifically, we had no role to play in the trading that happened in the week prior to the announcement wherein the share price of Ranbaxy went up. Silverstreet had previously bought these shares as a matter of investment. Pl. note at Sun Pharma, we always hold ourselves to the highest standards of corporate governance and business ethics. We believe that, as advised by our advisers , the article/judgement would not have material impact on the merger process of Ranbaxy with our Company".
Apr 2014